AtriCure Reports Preliminary Results for Fourth Quarter and Full Year 2025, Provides Financial Outlook for 2026
MWN-AI** Summary
AtriCure, Inc. (Nasdaq: ATRC), an innovator in surgical treatments for atrial fibrillation (Afib), reported its preliminary financial results for Q4 and the full year 2025, along with guidance for 2026. The company anticipates Q4 2025 revenue of approximately $140.5 million, marking a 13% increase over Q4 2024, with U.S. revenue expected to reach $114.3 million and international revenue at $26.2 million. The growth was driven by robust performance in its Pain Management, Open Ablation, and Open AtriClip® divisions.
For the entire year 2025, AtriCure projects revenue of about $534.5 million, a 15% rise from 2024. The company also expects to report a positive adjusted EBITDA of approximately $57 million to $59 million and an adjusted loss per share ranging from $0.18 to $0.21. At year-end, AtriCure's cash and investments totaled around $167 million.
Michael Carrel, AtriCure’s President and CEO, highlighted the company's successful product launches, the completion of the LeAAPS trial, and overall strong operational execution in 2025. The achievements reinforce AtriCure's long-term growth strategy, emphasizing increased global device adoption in 2026.
Looking ahead, AtriCure projects 2026 revenues between $600 million and $610 million, which would represent a growth of 12% to 14% compared to 2025. Management anticipates adjusted EBITDA of approximately $80 million to $82 million and a return to net income. The company remains committed to positive cash flow throughout 2026. AtriCure is dedicated to advancing treatments for the 59 million people affected by Afib and related conditions worldwide.
MWN-AI** Analysis
AtriCure, Inc. (Nasdaq: ATRC) has reported impressive preliminary financial results for both the fourth quarter and the full year of 2025, signaling a strong growth trajectory that investors should consider carefully. The fourth quarter revenue is expected to reach approximately $140.5 million, reflecting a robust 13% increase year-over-year. This is largely driven by significant demand for their Pain Management and AtriClip® devices. The full-year revenue outlook of $534.5 million also presents a solid 15% growth over 2024, which is indicative of AtriCure’s effective market strategies and innovation within the surgical treatment space for atrial fibrillation (Afib).
Looking ahead to 2026, AtriCure anticipates revenues to range between $600 million and $610 million, implying sustained growth of around 12% to 14%. This forecast is bolstered by expected advancements in market penetration and product adoption globally. Furthermore, the projected positive adjusted EBITDA of $80 million to $82 million could enhance investor confidence, as it suggests a healthier bottom line moving forward. The company’s cash reserves of approximately $167 million also offer a buffer for strategic investments or operational scaling.
However, potential investors should remain cautious. The risks outlined in AtriCure's forward-looking statements highlight challenges such as competition, regulatory hurdles, and market acceptance of new products. These factors may introduce volatility to their stock performance.
For current shareholders, the promising growth metrics encourage a bullish outlook; for potential investors, this could be an opportune time to consider entry into a company demonstrating both resilience and innovation in a vital healthcare niche. Monitoring the upcoming quarterly call in February may provide further insight and direction for investment strategies.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, today announced preliminary financial results for the fourth quarter and full year 2025 and provided 2026 financial guidance.
Preliminary, unaudited revenue for fourth quarter 2025 is expected to be $140.5 million, reflecting growth of approximately 13% over the fourth quarter of 2024 (12% on a constant currency basis). U.S. revenue is expected to be $114.3 million, reflecting growth of approximately 13%, and international revenue is expected to be $26.2 million, an increase of approximately 15% as reported (10% on a constant currency basis). Fourth quarter revenue was driven by continued strong growth in Pain Management, Open Ablation and Open AtriClip ® devices.
Preliminary, unaudited revenue for full year 2025 is expected to be $534.5 million, reflecting growth of approximately 15% over full year 2024 (14% on a constant currency basis). Management now expects full year 2025 positive adjusted EBITDA of approximately $57 million to $59 million, and full year 2025 adjusted loss per share of approximately $0.18 to $0.21. The Company ended the year with approximately $167 million in cash and investments. Adjusted EBITDA, adjusted loss per share and constant currency revenue growth are non-GAAP measures. AtriCure will provide a reconciliation of non-GAAP measures to the related GAAP measure in the release of audited 2025 results. Management will discuss financial results on the fourth quarter and full year 2025 conference call in February.
“2025 marked another outstanding year for AtriCure, highlighted by strong growth and transformative innovation. We successfully launched several new products, completed enrollment in our standards changing LeAAPS trial, and drove significant leverage in the business, all while strengthening our commitment to advancing patient care,” said Michael Carrel, President and Chief Executive Officer of AtriCure. “Our 2025 results demonstrate robust operating performance and execution of our strategic initiatives and reinforce the long-term growth trajectory provided at our 2025 Investor Day. In 2026, we are confident in delivering increased adoption of our devices globally.”
2026 Financial Guidance
Management projects 2026 revenue of approximately $600 million to $610 million, reflecting growth of approximately 12% to 14% over full year 2025. Management also projects full year positive adjusted EBITDA of approximately $80 million to $82 million in 2026 and anticipates full year net income in 2026. Additionally, management expects continued positive cash flow for 2026.
About AtriCure
AtriCure, Inc. provides innovative technologies for the treatment of Afib and related conditions. Afib affects more than 59 million people worldwide. Surgeons around the globe use AtriCure technologies for the treatment of Afib, reduction of Afib related complications and post-operative pain management. AtriCure’s Isolator ® Synergy™ Ablation System is the first medical device to receive FDA approval for the treatment of persistent Afib. AtriCure’s AtriClip ® Left Atrial Appendage Exclusion System products are the most widely sold LAA management devices worldwide. AtriCure’s Hybrid AF™ Therapy is a minimally invasive procedure that provides a lasting solution for long-standing persistent Afib patients. AtriCure’s cryoICE cryoSPHERE ® and cryoXT ® probes are cleared for temporary ablation of peripheral nerves to block pain, providing pain relief in cardiac, thoracic and amputation procedures. For more information, visit AtriCure.com or follow us on X @AtriCure.
Forward-Looking Statements
Except for historical information, certain statements in this press release, including financial guidance and outlook, are forward-looking in nature and are subject to risks, uncertainties and assumptions about us. Our business and operations are subject to a variety of risks and uncertainties and, consequently, actual results may differ materially from those projected by any forward-looking statements. These risks and uncertainties include, but are not limited to, the following: our estimate of the market for our products; the rate and degree of market acceptance of our products; negative clinical data; competition from existing and new products and procedures, including the development of drugs or catheter-based technologies; our reliance on independent distributors to sell our products; inventory-related charges; the timing of and ability to obtain and maintain regulatory clearances and approvals for our products; impacts of rising healthcare costs; our ability to comply with extensive FDA regulations; the timing of and ability to obtain third party payor reimbursement of procedures utilizing our products; unfavorable publicity; the potential impact of any acquisitions, mergers, dispositions, joint ventures or investments we may make; disruptions to our manufacturing operations; the impact of tariffs or other restrictive trade measures; our failure to properly manage growth; disruptions of critical information systems or material breaches in the security of our systems; our ability to manage our intellectual property rights to provide meaningful protection; fluctuation of quarterly financial results; fluctuations in foreign currency exchange rates; reliance on third party manufacturers and suppliers; and litigation, administrative or other proceedings. These risks and uncertainties, as well as others, are discussed in greater detail in our filings with the Securities and Exchange Commission ("SEC"), including our Annual Report on Form 10-K for the year ended December 31, 2024 filed with the SEC on February 14, 2025, and our quarterly reports on Form 10-Q. There may be additional risks of which we are not presently aware or that we currently believe are immaterial which could have an adverse impact on our business. Any forward-looking statements are based on our current expectations, estimates and assumptions regarding future events and are applicable only as of the dates of such statements. We make no commitment to revise or update any forward-looking statements in order to reflect events or circumstances that may change.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260112726620/en/
Angie Wirick
AtriCure, Inc.
Chief Financial Officer
(513) 755-5334
awirick@atricure.com
Marissa Bych
Gilmartin Group
Investor Relations
(415) 991-5386
marissa@gilmartinir.com
FAQ**
What specific factors contributed to the approximately 13% growth in AtriCure Inc. (Nasdaq: ATRC) revenue for the fourth quarter of 2025, particularly in the Pain Management segment?
How does AtriCure Inc. (Nasdaq: ATRC) plan to enhance the adoption of its devices globally in 2026, given its projected revenue growth of 1to 14%?
What are the main risks and uncertainties outlined by AtriCure Inc. (Nasdaq: ATRC) that could potentially affect the company's 2026 financial guidance and growth trajectory?
Can AtriCure Inc. (Nasdaq: ATRC) provide more details on its strategic initiatives implemented in 2025 that drove the strong operating performance and led to a positive adjusted EBITDA for the year?
**MWN-AI FAQ is based on asking OpenAI questions about AtriCure Inc. (NASDAQ: ATRC).
NASDAQ: ATRC
ATRC Trading
-1.98% G/L:
$29.21 Last:
639,601 Volume:
$29.66 Open:
